Latest revenue
$40.8M
as of 2026-03-31
Latest net income
$-93.2M
as of 2026-03-31
Net margin
-228.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.88B
- Enterprise value
- $2.88B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $118.84
- 52-wk low
- $29.95
- Beta
- —
- Shares out
- 42.9M
5-year trend
What this company does
Item 1. Business Our Company Our mission is to detect cancer early, when it can be cured. We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood…
AI summary unavailable — showing raw filing excerpt
Generated from GRAL's filing dated 2026-03-12
Key risks
Item 1A. Risk Factors You should carefully consider the following risks and other information in this Annual Report on Form 10-K in evaluating GRAIL and GRAIL common stock. Any of the following risks and uncertainties could materially adversely affect our business, financial condition, and results of operations. The following risks have generally been separated into five groups: risks relating to our business and industry, risks relating to regulation and legal compliance, risks relating to intellectual property, risks relating to the Spin-Off, and risks relating to our common stock. References to “we,” “our,” “us,” and words of similar import in this section refer to GRAIL and, unless…
AI summary unavailable — showing raw filing excerpt
Generated from GRAL's filing dated 2026-03-12
Profitability
Operating margin
-382.0%
78.1%Net margin
-277.5%
82.8%Return on equity
-15.8%
80.4%Return on assets
-14.0%
79.4%Leverage
Debt / equity
0.13×
30.4%Debt / assets
11.8%
26.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $40.8M | +28.1% | $-93.2M | +12.3% | -228.5% |
Q4 2025 2025-12-31 | $43.6M | +14.0% | $-99.2M | -2.2% | -227.5% |
Q3 2025 2025-09-30 | $36.2M | +26.3% | $-89.0M | +29.2% | -245.8% |
Q2 2025 2025-06-30 | $35.5M | +11.2% | $-114.0M | +92.8% | -320.7% |
Q1 2025 2025-03-31 | $31.8M | +19.1% | $-106.2M | +51.5% | -333.6% |
Q4 2024 2024-12-31 | $38.3M | — | $-97.1M | — | -253.8% |
Q3 2024 2024-09-30 | $28.7M | +38.3% | $-125.7M | +85.9% | -438.7% |
Q2 2024 2024-06-30 | $32.0M | +42.6% | $-1.59B | -721.2% | -4958.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on GRAL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$128.7M
Net activity
−$128.7M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns GRAL
Institutional value
$665.5M
Total shares held
13.0M
Distinct holders
243
-177 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.0M | $153.4M | +10.3K (+0.3%) | Added |
| 2 | PRIMECAP MANAGEMENT CO/CA/ | 1.8M | $95.3M | +5.1K (+0.3%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $78.9M | — | New |
| 4 | Arbiter Partners Capital Management LLC | 1.0M | $53.5M | -1.0K (-0.1%) | Trimmed |
| 5 | Jefferies Financial Group Inc. | 657.5K | $34.0M | — | New |
| 6 | DIMENSIONAL FUND ADVISORS LP | 408.6K | $21.1M | +191.9K (+88.5%) | Added |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 334.9K | $17.3M | — | New |
| 8 | CITIGROUP INC | 302.1K | $15.6M | +234.6K (+347.4%) | Added |
| 9 | Slow Capital, Inc. | 228.3K | $11.8M | +65.8K (+40.5%) | Added |
| 10 | abrdn plc | 217.4K | $11.2M | +92.5K (+74.0%) | Added |
| 11 | Carnegie Investment Counsel | 217.1K | $11.2M | +4.0K (+1.9%) | Added |
| 12 | VANGUARD FIDUCIARY TRUST CO | 201.2K | $10.4M | — | New |
| 13 | UBS Group AG | 185.4K | $9.6M | -27.8K (-13.0%) | Trimmed |
| 14 | Allianz Asset Management GmbH | 183.1K | $9.5M | -84.5K (-31.6%) | Trimmed |
| 15 | Douglas Lane & Associates, LLC | 161.5K | $8.3M | -100 (-0.1%) | Trimmed |
| 16 | BNP PARIBAS FINANCIAL MARKETS | 148.8K | $7.7M | +129.4K (+667.0%) | Added |
| 17 | FRANKLIN RESOURCES INC | 148.0K | $7.6M | +1.9K (+1.3%) | Added |
| 18 | Bank of New York Mellon Corp | 133.9K | $6.9M | -1.9K (-1.4%) | Trimmed |
| 19 | Invesco Ltd. | 129.0K | $6.7M | -9.0K (-6.5%) | Trimmed |
| 20 | 180 WEALTH ADVISORS, LLC | 127.3K | $6.6M | +12.3K (+10.7%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once GRAL's latest filing finishes processing.